FEVER

37
FEVER DENGUE VIRUS: NO ONE IS SAFE Prepared by: Mohamed Abdul Gader

description

FEVER. DENGUE VIRUS: NO ONE IS SAFE. Prepared by: Mohamed Abdul Gader. Alternative Names. West Nile Fever Break Bone Fever Dengue like Disease Onyong- Nyang Fever. WHAT IS DENGUE ?. Dengue is an arthropod-borne disease caused by any one of four closely related viruses. - PowerPoint PPT Presentation

Transcript of FEVER

Page 1: FEVER

FEVER

DENGUE VIRUS: NO ONE IS SAFE

Prepared by: Mohamed Abdul Gader

Page 2: FEVER

Alternative Names

• West Nile Fever

• Break Bone Fever

• Dengue like Disease

• Onyong- Nyang Fever

Page 3: FEVER

WHAT IS DENGUE ?

• Dengue is an arthropod-borne disease caused by any one of four closely related viruses.

• Infection with one serotype of dengue virus provides immunity to that serotype for life.

• A person can be infected as many as four times, once with each serotype.

Holly R. Hughes 2009

Page 4: FEVER

DENGUE (cont’d)

• Dengue virus (DEN) is a member of the Flavivirus genus in the Flaviviridae family of single-stranded, positive-polarity, enveloped RNA viruses.

• Dengue viruses are transmitted from person to person by Aedes mosquitoes (most often Aedes aegypti) in the domestic environment.

Burke, D. S., and T. P. Monath. 2001.

Page 5: FEVER

Dengue Virus

Electron Micrograms

Page 6: FEVER

• About 50–100 million cases of dengue fever and 500,000 cases of Dengue Hemorrhagic Fever (DHF), resulting in around 24,000 deaths, are reported annually.

• dengue is often found in urban areas of tropical nations, including Puerto Rico, Singapore, Malaysia, Taiwan, Thailand, Indonesia, Philippines, Pakistan, India, Brazil, Vietnam, Guyana, Venezuela, Bangladesh.

www.plosone.org 2008

Page 7: FEVER

• Dengue’s vectors are two types of Aedes mosquitoes; Aedes aegypti and Aedes albopictus. However, it is the Aedes aegypti species that is most notorious for transmitting dengue.

http://www.cdc.gov

Page 8: FEVER

1. Mosquitoes transmitdengue to human dendriticcells

2. Dengue targets areaswith high WBC counts(liver, spleen, lymph nodes, bone marrow, andglands)

3. Dengue enters

WBCs & lymphatic

tissue

4. Dengue enters bloodcirculation

3

4

1

2

3

HOW DENGUE SPREADS

Page 9: FEVER

Transmission of Dengue Virus by Aedes aegypti

http://www.cdc.gov

Page 10: FEVER

DENGUE (cont’d)

Three Manifestations:1. Dengue Fever2. Dengue Hemorrhagic Fever3. Dengue Shock Syndrome

Leads to death in 5% of cases

More dangerous if infected second time by different serotype

Page 11: FEVER

Dengue Fever

• Dengue Fever is an acute febrile illness of 2-7 days duration (sometimes with two peaks) with two or

more of the following manifestations:• Headache retro -orbital pain• myalgia/arthralgia rash• haemorrhagic manifestation (petechiae and positive

tourniquet test) .• leukopenia

Page 12: FEVER

Dengue Hemorrhagic Fever (DHF)

A severe form of Dengueresulting from a secondinfection of a different serotype of the virus

First serotype … Dengue fever … Recovery

Second serotype … Risk of DHF

Page 13: FEVER

http://www.cdc.gov/ncidod/dvbid/dengue/slideset/set1/images/petechiae2-small.jpg

P E T E C H I A E

Page 14: FEVER

P U R P U R A

http://www.pediatrics.wisc.edu/education/derm/tutb/85m.jpg

Page 15: FEVER

http://www-medlib.med.utah.edu/WebPath/ATHHTML/ATH036.html

E C C H Y M O S I S

Page 16: FEVER

http://www.cgste.mq/brainstorm/dengue/image/hemo.gif

NASAL HEMORRHAGING

Page 17: FEVER

Dengue Shock Syndrome

• Dengue Shock Syndrome (DSS) All the above

criteria of DHF plus signs of circulatory failure manifested by rapid and weak pulse, narrow pulse

pressure, hypotension for age, cold and clammy skin

and restlessness

Page 18: FEVER

IMMUNE RESPONSE

Stephenson, 2005

Page 19: FEVER

FIRST INFECTION

Humoral and cellular immune response

- Ab serum neutralizing levels increase

- T-lymphocytes activated by dendritic cells

- Memory cells develop antibodies to fight off future infection of same serotype

Stephenson, 2005

Page 20: FEVER

SECOND INFECTION

Antibody dependent enhancement

- Enhancing immunoglobulin G (IgG) antibodies

- Fc Receptors

Stephenson, 2005

Page 21: FEVER

IMMUNO PATHOGENECITY

• Dengue viruses replicate within the cytoplasm of infected cells after receptor-mediated entry

• The known sites of viral replication in vivo are leukocytes, especially circulating B cells, Kupffer cells, and tissue macrophages outside of the neuroaxis

• Infection of dendritic cells by dengue viruses may play an important role in disease pathogenesis

Magill, 2005

Page 22: FEVER

Continue …..

• Infection with one dengue virus type appears to confer lifelong homologous immunity but little to no heterologous immunity

• Complement is activated, generating vasoactive cleavage products C3a and C5a. Immune activation and the resulting cytokine and complement cascade appear to account for the plasma leakage and hemostatic defects that occur in DHF

Magill, 2005

Page 23: FEVER

Hypothesis on Pathogenesis of DHF -DSS

Persons who have experienced a dengue infection develop serum antibodies that can neutralize the dengue virus of that same (homologous) serotype

Page 24: FEVER

Homologous Antibodies Form- Non Infectious Complexes

Page 25: FEVER

In a subsequent infection, the pre-existing heterologous antibodies form complexes with the new infecting virus serotype, but do not neutralize the new virus.

Hypothesis on Pathogenesis of DHF-DSS

Page 26: FEVER

Heterologous Antibodies Form Infectious Complexes

Page 27: FEVER

Antibody-dependent enhancement is the process in which certain strains of dengue virus, complexed with non-neutralizing antibodies, can enter a greater proportion of cells of the mononuclear lineage, thus increasing virus production.

Hypothesis on Pathogenesis of DHF-DSS

Page 28: FEVER

Heterologous Complexes Enter More Monocytes, Where Virus Replicates

Page 29: FEVER

Infected monocytes release vasoactive mediators, resulting in increased vascular permeability and hemorrhagic manifestations that characterize DHF and DSS.

Hypothesis on Pathogenesis of DHF-DSS

Page 30: FEVER

Immunopathogenic Cascade of DHF/DSS

• Macrophage – monocyte infection • Previous infection with heterologous Dengue

serotype results in production of non protective antiviral antibodies

• These Ab bind to the virion’s surface Fc receptor and focus the Dengue virus on to the target cells – macro/monocytes

• T cell - cytokines, interferon, TNF alpha

Page 31: FEVER

• (Libraty, D.H., et al. 2004) Elevations of circulating levels of activation markers including soluble TNF receptors, soluble IL-2 receptors, and soluble CD8 have been shown to correlate with disease severity.

http://www.jci.org 2004

Page 32: FEVER

• (Jamuna vadivelue 2007) Cytotoxic T lymphocytes (CTL) play an important role in the elimination of dengue virus-infected cells. Identification of antigenic peptides recognized by dengue virus-specific CTL may suggest new ways to suppress viral replication and prevent persistent infection

Jamuna vadivelue 2007

Page 33: FEVER

• (Chen ST, Lin YL 2008) Dr. Yi-Ling Lin in the Institute of Biomedical Sciences found that dengue virus binds to a human macrophage surface lectin receptor called CLEC5A and stimulates proinflammatory cytokines release.

Lin YL 2008

Page 34: FEVER

Diagnosis

• Isolation of dengue virus• Increased IgM or IgG antibody titer• Dengue antigen detection by immunohistochemistry,

immunofluroscence, ELISA• PCR• leucopenia,thrompocytopenia

Page 35: FEVER

Treatment of DF

• No antiviral agents are of proven value• Supportive measures - Vector barrier• Avoid Aspirin and Steroids should not be used• Fluid replacement to avoid hemoconc.• Children below 12 require careful watch

for DHF / DSS

Page 36: FEVER

DHF / DSS

Intensive Care

Oxygen

Rehydration

Barrier Nursing

Mosquito Screen

Blood or platelet Transfusions

Page 37: FEVER

Thank Youfor Your Attention